ArticleFrontiers in integrative neuroscience2021
Home-Based Transcranial Direct Current Stimulation for the Treatment of Symptoms of Depression and Anxiety in Temporal Lobe Epilepsy: A Randomized, Double-Blind, Sham-Controlled Clinical Trial.
Article in Frontiers in integrative neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 6 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Efficacy of psychological and behavioral interventions for depressive symptoms in people with epilepsy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of home-based transcranial direct current stimulation (tDCS) on patients with depressive disorders: a systematic review and meta-analysis of randomized clinical trials.Scientific reports · 2025Pooled it
- Transcranial Electrical Stimulation in Treatment of Depression: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Challenges and future directions of transcranial direct current stimulation for depression: insights from a systematic review and meta-analysis.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Pooled it
- Transcranial direct current stimulation in the management of epilepsy: a meta-analysis and systematic review.Frontiers in neurology · 2024Pooled it
- TDCS at home for depressive disorders: an updated systematic review and lessons learned from a prematurely terminated randomized controlled pilot study.European archives of psychiatry and clinical neuroscience · 2023Pooled it
- Home use of low-intensity transcranial electrical stimulation in clinical practice: an IFCN handbook chapter.Clinical neurophysiology practice · 2026Review
- Treating depression at home with transcranial direct current stimulation: a feasibility study.Frontiers in psychiatry · 2024Article
- Transcranial direct current stimulation as treatment for major depression in a home treatment setting (HomeDC trial): study protocol and methodology of a double-blind, placebo-controlled pilot study.Pilot and feasibility studies · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a double-blind randomized clinical trial in order to examine the effects and the safety of home-based transcranial direct current stimulation (tDCS) on depressive and anxious symptoms of patients with temporal lobe epilepsy (TLE). We evaluated 26 adults with TLE and depressive symptoms randomized into two different groups: active tDCS (tDCSa) and Sham (tDCSs). The patients were first submitted to 20 sessions of tDCS for 20 min daily, 5 days a week for 4 weeks and then received a maintenance tDCS application in the research laboratory once a week for 3 weeks. The intensity of the current was 2 mA, applied bilaterally over the dorsolateral prefrontal cortex, with the anode positioned on the left side and the cathode on the right side. Participants were evaluated on days 1, 15, 30, and 60 of the study using the Beck Depression Inventory II (BDI). A follow-up evaluation was performed 1 year after the end of treatment. They were also evaluated for quality of life and for anxious symptoms as secondary outcomes. The groups did not differ in clinical, socioeconomic or psychometric characteristics at the initial assessment. There was no statistically significant difference between groups regarding reported adverse effects, seizure frequency or dropouts. On average, between the 1st and 60th day, the BDI score decreased by 43.93% in the active group and by 44.67% in the Sham group (ΔBDIfinal - initial = -12.54 vs. -12.20,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.